GenMont Biotech Inc Asset Resilience Ratio
GenMont Biotech Inc asset resilience ratio. GenMont Biotech Inc (3164) has an Asset Resilience Ratio of 13.40% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GenMont Biotech Inc (3164) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GenMont Biotech Inc (2003–2025)
Asset resilience ratio of GenMont Biotech Inc from 2003 to 2025. This chart shows how GenMont Biotech Inc's Asset Resilience Ratio has changed over time. Read GenMont Biotech Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GenMont Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is GenMont Biotech Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$228.21 Million | 13.4% |
| Total Liquid Assets | NT$228.21 Million | 13.40% |
Asset Resilience Insights
- Moderate Liquidity: GenMont Biotech Inc has 13.40% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
GenMont Biotech Inc Industry Peers by Asset Resilience Ratio
Compare GenMont Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
GenMont Biotech Inc Asset Resilience Ratio by Year (2003–2025)
GenMont Biotech Inc asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for GenMont Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.76% | NT$329.06 Million ≈ $10.37 Million |
NT$1.67 Billion ≈ $52.46 Million |
+5.24pp |
| 2024-12-31 | 14.52% | NT$248.13 Million ≈ $7.82 Million |
NT$1.71 Billion ≈ $53.83 Million |
-1.97pp |
| 2023-12-31 | 16.50% | NT$272.71 Million ≈ $8.59 Million |
NT$1.65 Billion ≈ $52.08 Million |
+0.74pp |
| 2022-12-31 | 15.76% | NT$267.26 Million ≈ $8.42 Million |
NT$1.70 Billion ≈ $53.43 Million |
+0.93pp |
| 2021-12-31 | 14.83% | NT$251.78 Million ≈ $7.93 Million |
NT$1.70 Billion ≈ $53.50 Million |
+3.03pp |
| 2020-12-31 | 11.80% | NT$190.28 Million ≈ $5.99 Million |
NT$1.61 Billion ≈ $50.81 Million |
-9.51pp |
| 2019-12-31 | 21.31% | NT$334.80 Million ≈ $10.55 Million |
NT$1.57 Billion ≈ $49.50 Million |
-21.00pp |
| 2018-12-31 | 42.31% | NT$701.60 Million ≈ $22.10 Million |
NT$1.66 Billion ≈ $52.25 Million |
+28.86pp |
| 2017-12-31 | 13.44% | NT$201.69 Million ≈ $6.35 Million |
NT$1.50 Billion ≈ $47.26 Million |
+4.45pp |
| 2016-12-31 | 8.99% | NT$126.24 Million ≈ $3.98 Million |
NT$1.40 Billion ≈ $44.23 Million |
-2.69pp |
| 2015-12-31 | 11.68% | NT$190.89 Million ≈ $6.01 Million |
NT$1.63 Billion ≈ $51.47 Million |
+12.49pp |
| 2014-12-31 | -0.81% | NT$-14.05 Million ≈ $-442.56K |
NT$1.74 Billion ≈ $54.88 Million |
-44.92pp |
| 2013-12-31 | 44.11% | NT$606.01 Million ≈ $19.09 Million |
NT$1.37 Billion ≈ $43.28 Million |
-4.03pp |
| 2012-12-31 | 48.15% | NT$687.66 Million ≈ $21.66 Million |
NT$1.43 Billion ≈ $45.00 Million |
-11.31pp |
| 2011-12-31 | 59.46% | NT$887.58 Million ≈ $27.96 Million |
NT$1.49 Billion ≈ $47.03 Million |
+71.86pp |
| 2010-12-31 | -12.40% | NT$-169.36 Million ≈ $-5.34 Million |
NT$1.37 Billion ≈ $43.02 Million |
-61.81pp |
| 2007-12-31 | 49.41% | NT$282.47 Million ≈ $8.90 Million |
NT$571.68 Million ≈ $18.01 Million |
+48.57pp |
| 2006-12-31 | 0.84% | NT$4.39 Million ≈ $138.18K |
NT$520.93 Million ≈ $16.41 Million |
-0.48pp |
| 2005-12-31 | 1.32% | NT$4.15 Million ≈ $130.87K |
NT$313.55 Million ≈ $9.88 Million |
-25.08pp |
| 2004-12-31 | 26.41% | NT$81.62 Million ≈ $2.57 Million |
NT$309.07 Million ≈ $9.74 Million |
-0.65pp |
| 2003-12-31 | 27.06% | NT$69.88 Million ≈ $2.20 Million |
NT$258.26 Million ≈ $8.14 Million |
-- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan … Read more